NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 – Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application
SHELTON, CT / ACCESSWIRE / May 17, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the...
MindHYVE.ai™ and KPSIAJ Sign Strategic MOU to Advance AI-Driven Innovation in Education and Healthcare Across Karachi